View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Chapter 2.4<br />
102<br />
References<br />
1. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So<br />
TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated<br />
interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic<br />
hepatitis B: a randomised trial. Lancet 2005;365:123-9.<br />
2. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW,<br />
Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a,<br />
lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med<br />
2005;352:2682-95.<br />
3. van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C,<br />
So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated<br />
interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose<br />
reduction and treatment discontinuation. Aliment Pharmacol Ther 2005;21:1163-71.<br />
4. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song<br />
BC, Janssen HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following<br />
antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum<br />
hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.<br />
5. ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE,<br />
Haagmans BL, de Man RA, Schalm SW, Janssen HL. Patterns of viral decline during PEGinterferon<br />
alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment<br />
response. Hepatology 2006;44:721-7.<br />
6. Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, Janssen HL.<br />
Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment<br />
response during Peg-interferon {alpha}-2b therapy. Gut 2005;54:1604-9.<br />
7. Hansen BE, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response<br />
to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of<br />
HBV DNA during treatment. J Med Virol 2010;82:1135-42.<br />
8. Mauryama NT, F. Takeuchi M. Prediction of an outcome using trajectories estimated from a<br />
linear mixed model. Journal of Biopharmaceutical Statistics 2009;19:779-790.<br />
9. Brant LJ, Sheng SL, Morrell CH, Verbeke GN, Lesaffre E, Carter HB. Screening for prostate<br />
cancer by using random-effects models. Journal of the Royal Statistical Society Series A -<br />
Statistics in Society 2003;166(part 1):51-62.<br />
10. Morrell CH, Brant LJ, Sheng S. Comparing approaches for predicting prostate cancer from<br />
longitudinal data, In Proceedings of the American Statistical Association, Alexandria,<br />
American Statistica Association, 2007.<br />
11. Steyerberg EW. Clinical Prediction Models. Springer, 2009.<br />
12. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect<br />
of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-70.